34881-45-3

Basic information

• Product Name: 1-bromo-2-isopropyl-4-methoxybenzene
• Synonyms: 1-bromo-2-isopropyl-4-methoxybenzene;4-Bromo-3-isopropylanisole
• CAS NO: 34881-45-3
• Molecular Formula: C₁₀H₁₃BrO
• Molecular Weight: 229.11362
• Mol File: 34881-45-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-bromo-2-isopropyl-4-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-2-isopropyl-4-methoxybenzene(34881-45-3)
• EPA Substance Registry System: 1-bromo-2-isopropyl-4-methoxybenzene(34881-45-3)

Safety Data

• Hazardous Substances Data: 34881-45-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-bromo-2-isopropyl-4-methoxybenzene is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing medications.
Used in Fragrance Industry:
1-bromo-2-isopropyl-4-methoxybenzene is utilized as a key intermediate in the creation of fragrances, enhancing the scent profiles of various products and providing unique olfactory experiences.
Used in Organic Synthesis:
1-bromo-2-isopropyl-4-methoxybenzene is employed as a reagent in organic synthesis, facilitating the production of a wide range of organic compounds for diverse applications.
Used in Dye and Pigment Manufacturing:
This chemical is used in the manufacturing of dyes and pigments, contributing to the coloration and appearance of various products, including textiles, plastics, and paints.
Used in Plastics and Polymer Production:
1-bromo-2-isopropyl-4-methoxybenzene plays a role in the production of plastics and polymers, influencing the properties and performance of these materials in various applications.
It is crucial to handle 1-bromo-2-isopropyl-4-methoxybenzene with care and follow proper safety measures to mitigate potential health and environmental risks associated with its use.

Upstream product

• 6380-20-7 3-isopropylanisole 
• 618-45-1 3-isopropylhydroxybenzene 
• 74-88-4 methyl iodide 
• 853271-15-5 2-(2-bromo-5-methoxyphenyl) propan-2-ol 
• 35450-36-3 methyl 2-bromo-5-methoxybenzoate 
• 16606-28-3 2-bromo-5-isopropyl-phenol 
• 16606-29-4 4-bromo-3-(propan-2-yl)phenol 

Downstream Products

• 142576-99-6 N,N-Diethyl-2-isopropyl-4-methoxybenzamide 
• 849192-02-5 tri-(o-isopropyl-p-methoxyphenyl)phosphine 
• 865305-07-3 5-bromo-4-isopropyl-2-methoxy-benzaldehyde 
• 865305-06-2 5-bromo-2-isopropyl-4-methoxy-benzaldehyde 
• 313667-09-3 4-methoxy-2-isopropylphenylboronic acid 
• 1359976-62-7 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-{5-[(4-bromophenyl)methyl]-2-methoxy-4-(propan-2-yl)phenyl}-D-glucitol 
• 1240305-17-2 (E)-N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-isopropyl-4-methoxy-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-2,2-dimethylbut-3-enamide 
• 161480-96-2 2-isopropyl-4-methoxylbenzoic acid 
• 16606-29-4 4-bromo-3-(propan-2-yl)phenol 
• 142577-00-2 N,N-Diethyl-2-isopropyl-4-methoxy-6-sulfamoylbenzamide 
• 157887-45-1 2-Diethylcarbamoyl-3-isopropyl-5-methoxy-benzenesulfonyl chloride 

Relevant articles and documents

Zwitterionic-Salt-Catalyzed Site-Selective Monobromination of Arenes

A zwitterionic-salt-catalyzed electrophilic monobromination of arenes with high regioselectivity has been developed. Under mild reaction conditions, a wide range of monobrominated aromatic compounds can be obtained in excellent yields. The reaction can be operated using an extremely low catalyst loading (0.05 mol %) with the inexpensive brominating agent N-bromosuccinimide. The versatility of this catalytic protocol has been demonstrated by the scale-up reaction with a 0.01 mol % catalyst loading to provide the selectively halogenated compound in quantitative yield.

METHOD FOR PRODUCING 1,5-ANHYDRO-1-SUBSTITUTED PHENYL-D-GLUCITOL COMPOUNDS

PROBLEM TO BE SOLVED: To provide a novel method for producing 1,5-anhydro-1-substituted phenyl-D-glucitol compounds useful as medicines having the action of inhibiting sodium-dependent glucose cotransporters 1. SOLUTION: The present invention provides a method for producing 1,5-anhydro-1-substituted phenyl-D-glucitol compounds represented by formula (XI), wherein, compounds represented by formula (II) are converted through a plurality of steps to produce the compounds represented by formula (XI). SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT

METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and

Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formu

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Compounds having activity as inhibitors of cytochrome P450RAI

Compounds having Formula 8 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.